AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03483402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse laser trabeculoplasty
Description: Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
Study NCT03597945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine with epinephrine
Description: lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
Study NCT03597945 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine with epinephrine
Description: lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
Study NCT03597945 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
Study NCT03597945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
Study NCT04283136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 2 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period
Study NCT04283136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 3 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period.
Study NCT04283136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 4 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period.
Study NCT04283136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 5 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period.
Study NCT00607386 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Idursulfase
Description: Solution for intravenous infusion, 0.5 mg/kg weekly
Study NCT04572984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBMCB
Description: endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
Study NCT02670863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
Study NCT02670863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant Formula
Description: Standard bovine milk-based term infant formula, fed ad libitum
Study NCT00061542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BETOPTIC S (betaxolol HCl)
Description: betaxolol HC)
Study NCT00061542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Gel-forming Solution (TGFS)
Description: timolol maleate 0.25% and 0.5%
Study NCT01306448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant capsule
Description: vibrating capsule
Study NCT01336582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxotere
Description: 70 mg/m2 for age of ≥ 65
Study NCT01336582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxotere
Description: 70 mg/m2 for age of ≥ 65
Study NCT01108146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 Hydrocortisone 10 mg
Description: Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone
Study NCT01108146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2 Hydrocortisone 30 mg
Description: Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo
Study NCT03119714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemirolast
Description: Treatment with pemirolast 200 mg bid for 14-16 days
Study NCT03119714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Treatment with placebo bid for 14-16 days
Study NCT01827670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: Test dentifrice containing 0.454% SnF
Study NCT01827670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate \[1000 parts per million (ppm) fluoride\]
Study NCT01142401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT01142401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT01142401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02017327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoprost
Description: Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
Study NCT02017327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumigan 0.01%
Description: Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
Study NCT02017327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumigan 0.03% Unit Dose
Description: Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
Study NCT00970853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOM Program home visiting
Description: Mixed professional home visiting program.
Study NCT00970853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
Study NCT02031770 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium bicarbonate
Description: Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
Study NCT02031770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: subjects will receive no treatment
Study NCT01486849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357
Description: Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
Study NCT01486849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets BID for 21 days
Study NCT01486849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG
Study NCT01486849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole 50 MG
Study NCT02662257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
Study NCT02662257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery.
Study NCT03237104 — intervention group
Intervention type: OTHER
Intervention: Immediate PT
Description: Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
Study NCT02742428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systematic ascites evacuation
Description: Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
Study NCT02742428 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acute paracentesis.
Description: Evacuation of a large (>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
Study NCT02742428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview.
Description: Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
Study NCT02742428 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview.
Description: Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
Study NCT02742428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life.
Description: Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
Study NCT02742428 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life.
Description: Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
Study NCT02742428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional status.
Description: Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
Study NCT02742428 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional status.
Description: Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
Study NCT00525993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib 90mg 14 days
Description: each patient in this group will receive 90mg once daily, for the 14 days treatment.
Study NCT00525993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib 60mg daily for 14 days
Description: Patients in this group will receive 60mg of the drug, daily
Study NCT01236300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system
Study NCT04534478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Patients will be randomized 1: 1 between the two arms of the study
Study NCT03761615 — intervention group
Intervention type: DEVICE
Intervention: Dexcom G6 CGM
Description: All women in the study will be given Dexcom G6 CGM and a study glucometer.
Study NCT02642445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Sympathetic Denervation
Description: We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
Study NCT01428284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Probenecid
Description: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
Study NCT02327637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Activity
Description: Ambulation 150 feet, two times per day
Study NCT02821507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus and cyclophosphamide
Study NCT03812640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl suture
Description: Corneal suture with Vicryl suture
Study NCT03812640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon suture
Description: Corneal suture with Nylon suture
Study NCT03297736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D CAD/CAM autograft prosthesis
Description: Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
Study NCT03297736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control device
Description: Surgical ossicular reconstruction with the standard available middle ear prosthesis.
Study NCT02477059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
Study NCT02477059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: La saline solution is administered by intravenous infusion.
Study NCT02567149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Cidofovir
Study NCT03570931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
Study NCT00005832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R115777
Description: 300mg/dose BID, PO, Days 1-21, q 28days
Study NCT04288154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS Device On
Description: The EMS Device will turned on during exercise as opposed to it being turned off for control group.
Study NCT04288154 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EMS Device Off
Description: The EMS Device will turned off during exercise as opposed to it being turned off for control group.
Study NCT02248727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: somofilcon A lens
Study NCT02248727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: somofilcon A lens
Study NCT01708642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Adrenaline infusion 0.05 microgram / kg / minute
Study NCT01708642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraoperative isotonic saline infusion as placebo for adrenaline.
Study NCT01701739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Multiple doses of aleglitazar
Study NCT01701739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: Single dose of digoxin
Study NCT02626897 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GENEActiv Original Accelerometer
Description: Wrist-worn device measuring accelerations as a measure of daily activity.
Study NCT02626897 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ActiGraph GT3X Accelerometer
Description: Wrist-worn device measuring accelerations as a measure of daily activity.
Study NCT03917823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
Study NCT03917823 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
Study NCT01392911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: High dose rifampicin
Study NCT01392911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin
Study NCT02679898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unloaded-Whole Body Vibration (WBVT)
Description: The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
Study NCT02679898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loaded-Whole Body Vibration (WBVT)
Description: The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
Study NCT03257007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
Study NCT02184078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT02184078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Study NCT03179332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® insulin lispro
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Study NCT03179332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp®
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Study NCT03179332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid®
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Study NCT00258674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medicare Claims Feedback
Description: Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
Study NCT01577992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa test
Description: Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
Study NCT01577992 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: determination of objective and subjective pain threshold
Description: Test without levodopa intake